Secondary bacterial pneumonia is a frequent complication of influenza, associated with high morbidity and mortality. We hypothesized that treatment with neutralizing influenza A antibody AT10_002 protects against severe secondary pneumococcal infection in a mouse model of influenza A infection. Influenza A (H3N2) virus-infected male C57Bl6 mice were treated intravenously with either AT10_002 or a control 2 days postinfection. Seven days later, both groups were infected with Streptococcus pneumoniae and killed 18 hours later. Mice receiving AT10_002 showed less loss of bodyweight compared with controls (+1% vs −12%, P < .001), lower viral loads in bronchoalveolar lavage fluids (BALFs) (7 vs 194 RNA copies per µL; P < .001), and reduced bacterial outgrowth in lung homogenates (3.3 × 10 1 vs 2.5 × 10 5 colonyforming units per mg; P < .001). The treatment group showed lower pulmonary wet weights, lower cell counts, and lower protein levels in BALF compared with controls.
Treatment with AT10_002 was associated with lower levels of tumor necrosis factor-α, interleukin (IL)-6, cytokine-induced neutrophil chemoattractant (KC), and interferon-γ in BALF and lower IL-6 and KC in lung homogenates. Treatment with anti-influenza antibody AT10_002 is associated with reduced weight loss, viral load, bacterial outgrowth, and lung injury in a murine model of secondary pneumococcal pneumonia following influenza infection. and H7 variants in vitro. 26 In the current study, we hypothesized that treatment with influenza antibody AT10_002 reduces disease severity in a mouse model of secondary pneumococcal infection following influenza virus infection. 
| MATERIALS AND METHODS

| Mice
| Experimental infection protocol
| Exsanguination and organ processing
Mice were anesthetized intraperitoneally with 7.5 μL/g bodyweight of a mixture of ketamine (16.8 mg/mL) and dexmedetomidine (27 μg/mL) in sterile saline (0.9%). Mice were bled by heart puncture.
Blood was collected in EDTA tubes, centrifuged at 800g for 10 minutes at 4°C, and plasma was stored at − 80°C for further analysis. The right lung lobes were harvested and homogenized in 4 volumes of sterile saline using an Omni-TH Tissue Homogenizer Cycle threshold (C t ) values above 40 were considered negative; viral load estimates were calculated based on C t values.
| Viral load measurement
| Bacterial outgrowth
Lung homogenates were diluted in serial 10-fold dilutions in sterile saline (0.9%) and plated on blood-agar plates. CFUs were counted after 12-hour incubation at 37°C with 5% CO 2 .
| Cytokine and chemokine assays
Lung homogenates were diluted with equal volumes of lysis buffer 
| Statistical analysis
Data are expressed as median and interquartile range, unless stated otherwise. Results of the intervention group were compared to those of the control group using Mann-Whitney U tests. P < .05 was considered to represent a statistical significant difference. 
| Influenza antibody treatment reduces lung injury after secondary pneumococcal pneumonia
Mice receiving AT10_002 influenza antibodies exhibited less pulmonary edema, as measured by a lower lung wet weight compared with VAN decreased mucocilliary velocity and bacterial clearance. 32 Furthermore, the innate host response can be dysregulated, including decreased phagocytosis of neutrophils 33, 34 and desensitization of alveolar macrophages. 35 The adaptive response can also be impaired during severe influenza infection, which may increase the susceptibility of the host to bacterial superinfection. F I G U R E 5 A,B, Total cell count and protein levels in BALF in influenza-infected mice with secondary pneumococcal pneumonia treated with AT10_002 influenza antibodies vs control. Measurements were performed after sacrifice at 18 hours after pneumococcal infection. BALF, bronchoalveolar lavage fluid F I G U R E 6 A-H, Pulmonary cytokines and chemokines in BALF and lung homogenate influenza-infected mice with secondary pneumococcal pneumonia treated with AT10_002 influenza antibodies vs control. Measurements were performed after sacrifice at 18 hours after pneumococcal infection. BALF, bronchoalveolar lavage fluid; IFN, interferon; IL, interleukin; KC, cytokine-induced neutrophil chemoattractant; TNF, tumor necrosis factor
In conclusion, we show that early treatment with influenza antibody AT10_002 significantly reduced weight loss, lung injury, bacterial outgrowth, and inflammation in a mouse model of influenza infection, followed by secondary pneumococcal pneumonia.
Currently, several phase 2 studies are ongoing with similar broadly neutralizing HA antibodies in primary influenza infection. 25 Results from these studies will help determine the significance of our promising findings.
